PH-0547 Quality assurance of Treatment Planning Systems: upgrading the NCS report 15

2021 ◽  
Vol 161 ◽  
pp. S431-S432
Author(s):  
Y. Jourani ◽  
A. Delor ◽  
W. Crijns ◽  
G. Bol ◽  
R.G.J. Kierkels ◽  
...  
2017 ◽  
Vol 51 (4) ◽  
pp. 469-474 ◽  
Author(s):  
Grzegorz Zwierzchowski ◽  
Grzegorz Bieleda ◽  
Janusz Skowronek

Abstract Background Fast and easily repeatable methods for commissioning procedures for brachytherapy (BT) treatment planning systems (TPS) are needed. Radiochromic film dosimetry with gamma analysis is widely used in external beam quality assurance (QA) procedures and planar film dosimetry is also increasingly used for verification of the dose distribution in BT applications. Using the gamma analysis method for comparing calculated and measured dose data could be used for commissioning procedures of the newly developed TG-186 and MBDCA calculation algorithms. The aim of this study was dosimetric verification of the calculation algorithm used in TPS when the CT/MRI ring applicator is used. Materials and methods Ring applicators with 26 and 30 mm diameters and a 60 mm intra-uterine tube with 60° angle were used for verification. Gafchromic® EBT films were used as dosimetric media. Dose grids, corresponding to each plane (dosimetric film location), were exported from the TPS as a raw data. Gafchromic® films were digitized after irradiation. gamma analysis of the data were performed using the OMNI Pro I’mRT® system, as recommended by the AAPM TG-119 rapport criterion for gamma analysis of 3%, 3 mm and a level of 95%. Results For the 26 mm and 30 mm rings, the average gamma ranged, respectively, from 0.1 to 0.44 and from 0.1 to 0.27. In both cases, 99% of the measured points corresponded with the calculated data. Conclusions This analysis showed excellent agreement between the dose distribution calculated with the TPS and the doses measured by Gafchromic films. This finding confirms the viability of using film dosimetry in BT.


2016 ◽  
Vol 193 (1) ◽  
pp. 46-54 ◽  
Author(s):  
Beatrice Steiniger ◽  
René Berger ◽  
Sabine Eilzer ◽  
Christine Kornhuber ◽  
Kathleen Lorenz ◽  
...  

2007 ◽  
Vol 34 (7) ◽  
pp. 2827-2836 ◽  
Author(s):  
Priscilla R. T. L. Camargo ◽  
Laura N. Rodrigues ◽  
Laura Furnari ◽  
Rodrigo A. Rubo

2020 ◽  
Vol 93 (1105) ◽  
pp. 20190161
Author(s):  
Robert I Johnstone ◽  
Teresa Guerrero-Urbano ◽  
Andriana Michaelidou ◽  
Tony Greener ◽  
Elizabeth Miles ◽  
...  

The aim of this article is to propose meaningful guidance covering the technical and safety issues involved when designing or conducting radiotherapy clinical trials that use MRI for treatment planning. The complexity of imaging requirements will depend on the trial aims, design and MRI methods used. The use of MRI within the RT pathway is becoming more prevalent and clinically appropriate as access to MRI increases, treatment planning systems become more versatile and potential indications for MRI-planning in RT are documented. Novel MRI-planning opportunities are often initiated and validated within clinical trials. The guidance in this document is intended to assist researchers designing RT clinical trials involving MRI, so that they may provide sufficient information about the appropriate methods to be used for image acquisition, post-processing and quality assurance such that participating sites complete MRI to consistent standards. It has been produced in collaboration with the National Radiotherapy Trials Quality Assurance Group (RTTQA). As the use of MRI in RT is developed, it is highly recommended for researchers writing clinical trial protocols to include imaging guidance as part of their clinical trial documentation covering the trial-specific requirements for MRI procedures. Many of the considerations and recommendations in this guidance may well apply to MR-guided treatment machines, where clinical trials will be crucial. Similarly, many of these recommendations will apply to the general use of MRI in RT, outside of clinical trials. This document contains a large number of recommendations, not all of which will be relevant to any particular trial. Designers of RT clinical trials must therefore take this into account. They must also use their own judgement as to the appropriate compromise between accessibility of the trial and its technical rigour.


Sign in / Sign up

Export Citation Format

Share Document